Genovis AB (publ.) (STO:GENO)

Market Cap	1.39B
Revenue (ttm)	123.19M
Net Income (ttm)	26.96M
Shares Out	66.06M
EPS (ttm)	0.41
PE Ratio	51.00
Forward PE	45.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,588
Average Volume	90,221
Open	22.55
Previous Close	22.70
Day's Range	20.80 - 22.80
52-Week Range	17.10 - 30.45
Beta	1.87
RSI	32.39
Earnings Date	Nov 7, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.